Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Market Size of the Onpattro Market In 2029?
The market size of onpattro, in recent years, has witnessed a HCAGR of XX. It is projected to boost from $XX million in 2024, escalating to $XX million in 2025 with a Compound Annual Growth Rate (CAGR) of XX%. The historic period growth can be attributed to factors such as increasing occurrence of hereditary transthyretin-mediated amyloidosis, heightened awareness of uncommon diseases, burgeoning investments in research and development, an aging demographic, and a surge in healthcare expenditure.
What Growth Rate Is Forecasted for the Onpattro Market by 2029?
The market size for onpattro is projected to experience a XX (FCAGR) expansion in the upcoming years, ultimately reaching an approximate value of $XX million by 2029 and displaying a compound annual growth rate (CAGR) of XX%. This growth over the forecast period can be credited to various factors such as partnerships and licensing, regulatory backing, a rise in chronic disease incidences, growing partnerships in the biopharmaceutical industry, and an increase in the amount of transthyretin amyloidosis cases. Key trends in the forecast period encompass the growing acceptance of ribonucleic acid-based therapies, increase in orphan drug designations, incorporation of digital health tools, a shift towards personalized medicine, and advancements in drug delivery technology.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20169&type=smp
Which Key Companies Are Shaping the Future of the Onpattro Market?
Major companies operating in the onpattro market include Alnylam Pharmaceuticals Inc.
Which Factors Are Driving Demand in the Onpattro Industry?
The escalating occurrence of hereditary transthyretin-mediated amyloidosis (hATTR) is predicted to fuel the expansion of the onpattro market. hATTR is a rare genetic condition in which damaging deposits are formed by mutated TTR proteins, impacting nerves and the heart. The escalating occurrence of hATTR is triggered by enhanced diagnostics, genetic testing and rising awareness, which helps in identifying more cases. Onpattro is employed to manage hATTR by muting the transthyretin (TTR) gene, thus reducing amyloid protein production and inhibiting organ harm. For instance, as mentioned by Verywell Health, a US health information platform, in February 2024, hATTR impacts approximately 5,500–38,500 people globally, with U.S. figures ranging from 104 to 3,847 cases of hATTR with polyneuropathy, underlining a significant underdiagnosis. Therefore, the escalating prevalence of hATTR is pushing the expansion of the onpattro market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=20169&type=smp
How Is the Onpattro Market Segmented by Several Divisions?
The onpattro market covered in this report is segmented –
1) By Clinical Indication: Hereditary Transthyretin-Mediated Amyloidosis, Wild-Type Transthyretin Amyloidosis, Other Transthyretin-Related Amyloidoses
2) By Distribution Channel: Direct Sales, Pharmacies, Online Pharmacies
3) By End User: Hospitals, Specialty Clinics, Home Healthcare Providers
What are the Emerging Market Trends Driving the Growth of the Onpattro Industry?
The prevailing trend in the onpattro market revolves around diversifying the applications of the drug. This is being achieved through the submission of supplemental drug applications, aiming to tap into its full market potential and cater to a broader spectrum of patient needs. In essence, the supplemental drug applications intend to widen a drug’s therapeutic span and market scope by extending its approved usage, which could include targeting new indications, populations, or formulations. An example of this can be seen with Alnylam Pharmaceuticals, an American pharmaceutical firm that announced the approval of a Supplemental New Drug Application (sNDA) for their drug ONPATTRO (patisiran) in February 2023. ONPATTRO, an RNA interference (RNAi) therapeutic, is specifically designed to target the transthyretin (TTR) protein, which can abnormally accumulate in patients with transthyretin amyloidosis (ATTR), potentially causing serious complications such as cardiomyopathy. Initially, the drug was sanctioned in 2018 for treating polyneuropathy in hereditary ATTR amyloidosis patients. The recent sNDA was submitted following the findings from the Phase III APOLLO-B study, which revealed that patisiran markedly enhanced the functional capacity and quality of life in cardiomyopathy patients compared to a placebo.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/onpattro-global-market-report
Which Regions Are Driving Growth in the Onpattro Market?
North America was the largest region in the onpattro market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onpattro market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20169
This Report Delivers Insight On:
1. How big is the onpattro market, and how is it changing globally?
2. Who are the major companies in the onpattro market, and how are they performing?
3. What are the key opportunities and risks in the onpattro market right now?
4. Which products or customer segments are growing the most in the onpattro market?
5. What factors are helping or slowing down the growth of the onpattro market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model